Etrasimod Significantly Improves Atopic Dermatitis in Phase 2b Trial
Etrasimod, an investigational drug for moderate to severe atopic dermatitis, demonstrated statistically significant improvements in a phase 2b clinical trial, according to a study presented at AAD VMX 2021.